TheProfitWatch

AVTX - Avalo Therapeutics, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
18.46 -0.73 (-3.95%) --- 0.03 (0.14%) 0.09 (0.54%) 0.0 (0.0%) -0.26 (-1.45%) 0.0 (0.0%) 0.36 (1.99%)

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
-1.92
Diluted EPS:
-1.92
Basic P/E:
-9.2344
Diluted P/E:
-9.2344
RSI(14) 1m:
54.95
VWAP:
17.72
RVol:

Events

Period Kind Movement Occurred At

Related News